Trial Profile
The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics
- 30 Aug 2023 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 30 Aug 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Jun 2024.
- 20 Sep 2022 Planned End Date changed from 1 Dec 2022 to 1 Jan 2024.